Relationship between the detection rate of EpCAM-positive circulating tumor cells (CTCs) in metastatic breast cancer patients and the CTC enrichment technology.
Robert Königsberg(Kaiser-Franz-Josef-Spital), C. Dittrich(Kaiser-Franz-Josef-Spital), Eva Obermayr(Comprehensive Cancer Center Vienna), Marcus Hudec(University of Vienna), Robert Zeillinger(Comprehensive Cancer Center Vienna), Margit Gneist(Kaiser-Franz-Josef-Spital), Georg Pfeiler(Medical University of Vienna), Reinhard Ruckser(Donauspital)
Cited by 1
Related Papers
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2021|255
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients
|Acta Oncologica|2011|239